Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study represents a phase I clinical trial that utilizes natural killer (NK) cell therapy
for patients diagnosed with liver cancer, specifically those classified as Child-Pugh A and
falling within the Barcelona Clinic Liver Cancer (BCLC) stages B or C. The expected results
include determining the suitable treatment dosage, identifying any resulting side effects,
and calculating the average duration of progression-free survival. The target group for the
study consists of all individuals diagnosed with liver cancer. At the same time, the
practical sample consists of those who received medical care for liver cancer at Cipto
Mangunkusumo Hospital (RSCM) between May and December 2022. The chosen research sample
comprises liver cancer patients who fulfill the predetermined participation criteria. The
necessary sample size for discerning appropriate treatment dosages and the occurrence rate of
potential side effects shall consist of 2-3 liver cancer patients who are administered
autologous NK cells. The process for isolating these NK cells adheres to the guidelines
established by Miltenyi Biotec.